Completed PHASE2 INTERVENTIONAL 5-arm NCT01854047

An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma

Sponsor: Regeneron Pharmaceuticals

Conditions Asthma

Interventions Dupilumab ICS/LABA therapy Levosalbutamol/levalbuterol Salbutamol/albuterol placebo

Updated 8 times since 2017 Last updated: Jun 7, 2017 Started: Jun 30, 2013 Primary completion: Nov 30, 2014 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01854047, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by Regeneron Pharmaceuticals, it has been updated 8 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jul 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jul 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals
Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Albany, United States , Amasya, Turkey (Türkiye) , Ancona, Italy , Ankara, Turkey (Türkiye) , Asahi-Shi, Japan , Baltimore, United States , Barcelona, Spain , Bialystok, Poland , Brest, France and 149 more locations